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Summary of Research
The research done under the cooperative research agreement for the project titled "The
structure and function of non-collagenous bone proteins" represented the first phase of an
ongoing program to define the structural and functional relationships of the principal non-
collagenous proteins in bone. An ultimate goal of this research is to enable design and
execution of useful pharmacological compounds that will have a beneficial effect in
treatment of osteoporosis, both land-based and induced by long-duration space travel. The
goals of the now complete first phase were as follows:
1. Establish and/or develop powerful recombinant protein expression systems;
2. Develop and refine isolation and purification of recombinant proteins;
3. Express wild-type non-collagenous bone proteins;
4. Express site-specific mutant proteins and domains of wild-type proteins to enhance
likelihood of crystal formation for subsequent solution of structure.
The goals as stated in the initial proposal have been achieved, and are summarized in the
following.
Expression Systems
Our laboratory has established and is effectively producing recombinant proteins using the
following expression systems:-
a) prokaryotic systems pGEX, pMAL, and pQE; and
b) eukaryotic systems, baculovirus (insect cells), pischia pastoris (yeast), and vaccinia-
vires/T7 phage (mammalian cells).
These systems have been optimized for the production of high levels of recombinant
protein.
Purification and Mass Production
Purification of recombinant proteins produced in all expression systems has been facilitated
by use of fusion tags. Solubility of recombinant decorin produced in prokaryotic cells has
been enhanced by fusion to a maltose binding protein; for expression of other proteins the
poly-histidine sequence has proved to be most effective. The vaccinia expression system
has been extensively refined by the development of five new expression vectors that will
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facilitate both cloning, expression, and purification of recombinant proteins (vectors pT-
caml through pT-cam5). Biglycan and decorin have been expressed in eukaryotic cells as
fully processed glycoproteins and been extensively characterized (see J. Biol. Chem. 27 I,
19571 and J. BioL Chem. 27 I, 19578). Mass production of proteins by prokaryotic (10-
100 mg/l) and eukaryotic (20-40 mg/1) systems has now been achieved and preliminary
crystallization studies initiated by our colleagues at UAB. Production of osteopontin in the
prokaryotic system has yielded high levels of purified protein (see Ann. NYAcad. Sci.
760, 327), and crystallization is ongoing.
Mutant proteins
It is likely that the extensive post-translational processing non-collagenous bone proteins
undergo may prove to be problematic to crystallization (although likely to be functionally
important), therefore we are currently developing a range of mutant constructs that have
deleted or modified carbohydrate attachment sites. In addition, we are now able to express
recombinant proteins in mammalian CHO cells for which there exists a range of
glycosylation mutants; biglycan and decorin constructs in which the glycosaminoglycan
attachment site has been changed are being expressed in the Lec 1 CHO mutant that will put
a limited N-linked oligosaccharide on the core protein. Secondary structure appears not to
be affected and mass production is underway for crystallization experiments.
Wild-type and truncated mutants of bone sialoprotein constructs have been developed for
expression in eukaryotic cells; the recombinant protein produced by prokaryotes is
insoluble due to the absence of correct processing.
Decorin and decorin truncates expressed in the pMAL system have been used to identify a
divalent metal cation (Zn ++) binding site that may prove to be functionally important, in
addition to possibly stabilizing structures for crystal formation.
In conclusion, progress on this project is extremely encouraging and we are hopeful of-
producing high quality crystals for X-ray diffraction in the current phase of the program.
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PROGRESS REPORT (Part of Final Report, Round I)
The versatility of the vaccinia expression system has been greatly expanded by the
development of a panel of fusion protein expression constructs (Fig. 1). These plasmids,
pT-caml through pT-cam5, enable expression of matrix glycoproteins in eukaryotic cells
with or without an exogenous insulin signal sequence (to target nascent protein for
processing and secretion), a poly-histidine domain either at the N-terminal or C-terminal
end (for rapid, single-step affinity purification), and contain an extensive multicloning site
for convenient insertion of heterologous genes.
Biglycan and Decorin, small interstitial proteoglycans that can regulate collagen
fibrillogenesis in vitro and appear to be important in modulating the action of TGF-13 (an
agonist of osteoclast and osteoblast activity) have been expressed in large quantity (>20 mg
per experiment) by use of recombinant vaccinia viridae. Biglycan has been expressed both
as a proteoglycan (i.e. with 2 GAG chains) and as a core protein form (i.e. devoid of GAG
chains) containing two N-linked oligosaccharides. Crystal formation is more likely with
the later form so culture conditions were modified so that chemical amounts of purified core
protein have been purified and are currently undergoing crystallization screening at UAB.
Decorin similarly has been expressed as both a proteoglycan and core protein form;
however, the core protein is variably substituted with 2-3 N-linked oligosaccharides. We
have generated site-specific mutations in the core protein so that both the GAG attachment
and the 3rd oligosaccharide attachment site have been deleted; expression of chemical
amounts of homogeneous core protein is underway and will be sent for crystallization.
Both biglycan and decorin possess extensive secondary structure (far UV CD-spectra), and
this project represents the first time that these molecules have been produced in significant
amount with maintenance of secondary structure. The likelihood of finding conditions for
crystal formation and subsequent solving of the structure is high.
Recombinant vaccinia viridae encoding full length bone sialoprotein (BSP) and epiphycan
as poly-histidine fusion proteins have been generated and are now ready for large scale
production. BSP is a bone-specific protein and undergoes osteoblast-specific post-
translational modifications; expression will be done using osteoblast cultures propagated in
the STLV system of Dr. Neal Pellis (NASA). Similarly, epiphycan expression is restricted
to the growth plate of developing cartilage and it therefore likely that cultures of growth
plate chondrocytes that maintain an appropriate phenotype in the STLV system will be
optimized for large scale production.
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